BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $32.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by HC Wainwright from $30.00 to $32.00 in a research report report published on Monday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.11 EPS, FY2026 earnings at $0.05 EPS, FY2027 earnings at $0.31 EPS, FY2028 earnings at $0.88 EPS and FY2029 earnings at $1.31 EPS.

A number of other analysts also recently commented on the company. TD Cowen assumed coverage on BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target for the company. Zacks Research cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, December 2nd. Cantor Fitzgerald lifted their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 15th. Finally, Needham & Company LLC cut their price target on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $7.13 on Monday. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The stock has a market cap of $1.50 billion, a PE ratio of -142.60, a price-to-earnings-growth ratio of 0.72 and a beta of 0.91. The firm’s 50-day simple moving average is $7.17 and its 200 day simple moving average is $8.17.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The firm had revenue of $159.40 million during the quarter, compared to analysts’ expectations of $162.91 million. During the same quarter last year, the business posted ($0.07) EPS. The company’s quarterly revenue was up 36.1% on a year-over-year basis. As a group, analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Insider Activity

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 19,770 shares of the business’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $7.65, for a total value of $151,240.50. Following the sale, the insider directly owned 345,476 shares in the company, valued at $2,642,891.40. The trade was a 5.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 161,680 shares of company stock valued at $1,164,401 in the last 90 days. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Family Legacy Financial Solutions LLC purchased a new position in BioCryst Pharmaceuticals during the second quarter valued at approximately $72,000. Focus Partners Wealth bought a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at $77,000. Farther Finance Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 326.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 8,109 shares during the period. Vestmark Advisory Solutions Inc. purchased a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of BioCryst Pharmaceuticals in the third quarter worth $81,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.